56 active not recruiting. 56 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Active not recruiting 56 |
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 3 | 4 | Active not recruiting 4 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions Vancomycin (IV) - Healthy Volunteer, Hypersensitivity Reactions | Phase 1 / Phase 2 | Active not recruiting | Johns Hopkins University | 25 | 2026-05-21 | 2026-10-27 |
| Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis menthol-based hand and foot gloves, Sham menthol-based hand and foot gloves - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Taiwan Municipal An-Nan Hospital-China Medical University | 44 | 2026-04-29 | 2026-07-09 |
| A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis JNJ-95597528, Placebo - Dermatitis, Atopic | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 189 | 2026-01-20 | 2026-09-25 |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis Afimkibart - Atopic Dermatitis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 120 | 2026-01-08 | 2026-10-26 |
| A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Galvokimig, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | UCB Biopharma SRL | 165 | 2025-12-29 | 2026-09-25 |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis KT-621, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Kymera Therapeutics, Inc. | 200 | 2025-11-24 | 2026-10-06 |
| Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis GIA632, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2025-11-10 | 2026-05-14 |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks Vonoprazan, Placebo - Eosinophilic Esophagitis | Phase 2 | Active not recruiting | Phathom Pharmaceuticals, Inc. | 95 | 2025-10-30 | 2026-10-13 |
| A Study Evaluating TRIV-509 in Atopic Dermatitis TRIV-509, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Triveni Bio | 95 | 2025-08-26 | 2026-04-27 |
| A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis BFB759, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Bluefin Biomedicine, Inc. | 225 | 2025-07-15 | 2026-07-30 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis ATI-045, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Active not recruiting | Aclaris Therapeutics, Inc. | 110 | 2025-05-30 | 2026-09-29 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) BLU-808, Placebo - Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 105 | 2025-05-28 | 2026-07-22 |
| A Study for HSK44459 in Participants With Atopic Dermatitis HSK44459, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Xizang Haisco Pharmaceutical Co., Ltd | 150 | 2025-05-22 | 2026-01-02 |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) Verekitug, Placebo - Severe Asthma | Phase 2 | Active not recruiting | Upstream Bio Inc. | 396 | 2025-05-21 | 2026-05-14 |
| Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects MG-ZG122 Humanized Monoclonal Antibody Injection, Placebo - Bronchial Asthma | Phase 2 | Active not recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 160 | 2025-05-11 | 2025-07-08 |
| A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis Afimkibart, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 162 | 2025-04-01 | 2026-08-10 |
| A Phase 2 in Adult Subjects With Hereditary Angioedema BW-20805 - Hereditary Angioedema (HAE) | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 25 | 2025-02-28 | 2026-04-17 |
| A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma GSK5784283, Placebo - Asthma | Phase 2 | Active not recruiting | GlaxoSmithKline | 307 | 2025-02-10 | 2026-10-26 |
| A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma 610, Placebo - Asthma | Phase 2 | Active not recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 225 | 2024-12-20 | 2026-01-29 |
Showing 20 of 56. Sign in to see all of them.
Dermatitis, Atopic (23) · Asthma (14) · Eczema (7) · Angioedemas, Hereditary (5) · Dermatitis (3) · Eosinophilic Esophagitis (3) · Immune System Diseases (2) · Rhinitis, Allergic (2) · Alveolitis, Extrinsic Allergic (1) · Angioedema (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Asthma, Aspirin-Induced (1) · Bronchial Diseases (1) · Chronic Inducible Urticaria (1)
Immune System Diseases (54) · Hypersensitivity, Immediate (51) · Skin Diseases (31) · Skin and Connective Tissue Diseases (31) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (28) · Genetic Diseases, Inborn (28) · Skin Diseases, Eczematous (24) · Skin Diseases, Genetic (23) · Dermatitis (22) · Respiratory Hypersensitivity (18) · Respiratory Tract Diseases (18) · Lung Diseases (15) · Bronchial Diseases (14) · Lung Diseases, Obstructive (14)
dupilumab (5) · Sodium Chloride (2) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Albuterol (1) · Antigens, Dermatophagoides (1) · Betamethasone Valerate (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Calcineurin Inhibitors (1) · EpiCeram (1) · Fluticasone (1) · Fluticasone-Salmeterol Drug Combination (1) · Formoterol Fumarate (1)
Sanofi (3) · Hoffmann-La Roche (2) · ADARx Pharmaceuticals, Inc. (1) · AbbVie (1) · Aclaris Therapeutics, Inc. (1) · Apogee Therapeutics, Inc. (1) · Aravax Pty Ltd (1) · Astria Therapeutics, Inc. (1) · Avalyn Pharma Inc. (1) · Bio-Thera Solutions (1) · BioMarin Pharmaceutical (1) · Bluefin Biomedicine, Inc. (1) · Blueprint Medicines Corporation (1) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1)
United States (41) · Canada (22) · Germany (21) · Poland (21) · Spain (17) · United Kingdom (15) · Czechia (13) · Australia (12) · Italy (12) · Japan (12) · China (11) · France (9) · Bulgaria (8) · Argentina (7) · Brazil (7)
Andrew W Lee, MD (1) · Anne K Ellis, MD (1) · Brian Vickery, MD (1) · Daniel J. Jackson, M.D. (1) · Donghun Lee, M.D, Ph.D (1) · James G Krings, MD MSc (1) · Justin Salciccioli, MD (1) · Kari Nadeau, MD, PhD (1) · Katherine Cahill, MD (1)
PMID 30954166, PMID 32453217, PMID 33242697, PMID 36471430, PMID 36948586, PMID 37753954, PMID 38294975, PMID 39445704, PMID 40739793, PMID 41331725, PMID 41422501, PMID 41448793, PMID 41567689
2025 (5), 2023 (3), KL2TR002346 (1), R21AI182531 (1), U01AI147462 (1), U01AI155299 (1), U01AI158460 (1), U01AI179563 (1), U19AI095219 (1), UL1TR002345 (1)